Navigation Links
Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
Date:4/20/2012

CHAPEL HILL, N.C., April 20, 2012 /PRNewswire/ -- There are some two dozen oncology therapies in Phase III testing and many more are in earlier stages of development. While only some of these therapies will make it to launch, those that do will face yet another hurdle: a competitive marketplace where success revolves around planning as much as science.

In this environment, pharmaceutical organizations in the oncology therapeutic area must constantly evaluate which factors play the biggest role in the current launch landscape. One pharma company with promising products in its development pipeline wanted to know what launch success and failure factors play the biggest role in the current launch environment.

To answer this question, Best Practices, LLC conducted a wide-ranging field research project that explores the pivotal success factors and failure points facing new oncology product launches. The research established a critical core set of factors that can make or break a market entry for cancer products as well as other types of therapies.

The study, Success Factors and Failure Points in Oncology Product Launches, presents a framework for launch success:

  • The ability to differentiate
  • A defined target patient population
  • Investment in launch activities
  • Engagement of thought leaders
  • Education of key stakeholders
  • Demonstration of value
  • Utilization of new technologies
  • Avoidance of launch pitfalls

In terms of educating and winning support from key stakeholders, the study found that companies need to focus on different constituents during three critical early periods in a product's lifecycle (Market Entry, Win Share and Grow Share).

When entering the market, oncology launch leaders said companies need to focus on educating KOLs and payers; when trying to win share, the focus shifts to KOLs and specialists; and when trying to grow market share, it's important to focus on specialists and policymakers/government.

The 173-page report examines each of the key issues that are part of the framework for launch success and offers launch leaders two perspectives: an oncology segment and a total benchmark class segment that includes other therapeutic areas. In addition to delivering qualitative and quantitative insights on each aspect of this launch framework, the report presents launch leaders' perspectives on the current and future risk levels for an array of pitfall factors that can affect a launch.

To download a complimentary study excerpt, go to: http://www3.best-in-class.com/re1905.htm.

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 44 managers and executives at 38 leading bio-pharma companies participated in the survey.  In-depth interviews were conducted with leaders from six organizations.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Cepheid Reports 2012 First Quarter Results
3. New Report - Computed Tomography (CT) Market is Expected to Reach USD 5.6 Billion Globally in 2017: Transparency Market Research
4. Sotera Wireless Reports FDA Clearance of ViSi Mobile™ System
5. Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2
6. Solta Medical to Report First Quarter 2012 Results Release and Host Conference Call on May 1
7. Pharmos Corporation Reports First Quarter 2012 Results
8. Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations
9. NxStage® to Report First Quarter Fiscal 2012 Financial Results
10. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
11. Assured Pharmacy Reports Results for the Fiscal Year 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... ... Austin Oral Surgery – an oral and maxillofacial surgery practice with 11 ... has joined the practice. An accomplished oral and maxillofacial surgeon, Dr. Szalay’s primary responsibility ... open this fall. The new office is slated for 1601 E. Pflugerville Parkway, Building ...
(Date:8/27/2020)... ... 2020 , ... Bleep LLC, maker of the DreamPort mask-less CPAP solution, announced ... new spokesperson. , “In my line of work, a good night of sleep is ... it was a Bleeping no brainer for me,” said Jensen. “From the moment I ...
(Date:8/27/2020)... ... 2020 , ... Bridge To A Cure Foundation announces the appointment of Henry ... neuro-oncologist who serves on the Board of Directors at The Preston Robert Tisch Brain ... , Internationally recognized, Dr. Friedman is a widely published author of more than 500 ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... , ... The pandemic and topsy-turvy economic outlook continues to put financial strain on many of ... trim the fat from our monthly expenses and put more into savings, if possible. , ... have a financial safety net in place in case something were to happen to you,” ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, LLC, a venture-backed ... heart failure, today announced that the company has been awarded a Phase 1 ... National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... subscription to a customized Lighthouse Health & Wellness mobile app and web-portal. NCPCV ... project. Motorola Solutions Foundation awards grants each year to organizations, such as Destination ...
(Date:8/28/2020)... ... 2020 , ... A July 27 article on ... an increased risk of developing severe COVID-19 symptoms. The article does not suggest ... same organ systems that the coronavirus attacks are already suffering from the adverse ...
(Date:8/26/2020)... ... August 26, 2020 , ... Smile Brands Inc. CEO, ... Online Forum, leading a session entitled, “A CEO Guide for Delivering and Measuring ... designed to bring together the world’s leading diversity and inclusion executives, HR consultants, ...
Breaking Medicine News(10 mins):